Enliven Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Enliven Therapeutics (ELVN).

Price Target Range — 10 Quarters

Analyst Consensus — 11 Analysts

11Buy

Consensus RatingBuy# Analysts11Avg. Consensus PT$66Upside to Avg. PT+39.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	JP Morgan	Priyanka Grover	Initiate	Overweight	$75
Aug 18, 2026	William Blair	Andy Hsieh	Initiate	Outperform	—
Aug 18, 2026	Barclays	Etzer Darout	Initiate	Overweight	$78
Aug 18, 2026	Mizuho	Salim Syed	PT Raise	Outperform	$62→$73
Aug 6, 2026	Stifel	Dara Azar	PT Raise	Buy	$80→$82
Aug 6, 2026	Guggenheim	Michael Schmitz	PT Cut	Buy	$80→$78
Aug 6, 2026	Goldman Sachs	Salveen Richter	PT Raise	Buy	$67→$80
Jul 21, 2026	Goldman Sachs	Salveen Richter	PT Raise	Buy	$59→$67
Jul 9, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$56→$64
Jul 1, 2026	Stifel	Dara Azar	PT Raise	Buy	$60→$80
Jun 29, 2026	Jones Trading	Boris Peaker	PT Raise	Buy	$45→$70
Jun 9, 2026	Stifel	Dara Azar	Initiate	Buy	$60
Jun 2, 2026	Mizuho	Salim Syed	PT Raise	Outperform	$45→$62
May 8, 2026	Goldman Sachs	Salveen Richter	PT Raise	Buy	$41→$59
Mar 26, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$48→$56
Mar 25, 2026	Mizuho	Salim Syed	PT Raise	Outperform	$41→$45
Jul 2, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$40→$48
Jun 16, 2025	Goldman Sachs	Salveen Richter	Initiate	Buy	$37
Jun 16, 2025	Baird	Colleen Kusy	PT Raise	Outperform	$40→$52
May 16, 2025	Jones Trading	Soumit Roy	PT Cut	Buy	$36→$27

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75

JP Morgan analyst Priyanka Grover initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $75.

Benzinga Newsdesk

Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.

Vandana Singh

PRO
William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating

William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78

Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $78.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73

Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $62 to $73.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $82

Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $80 to $82.

Benzinga Newsdesk

Enliven Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Enliven Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75

Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

PRO
William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating

PRO
Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78

PRO
Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73

PRO
Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $82

People Also Watch

People Also Watch

Enliven Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Enliven Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75

Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

PROWilliam Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating

PROBarclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78

PROMizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73

PROStifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $82

People Also Watch

People Also Watch

PRO
JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75

PRO
William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating

PRO
Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78

PRO
Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73

PRO
Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $82